TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
NCT02676076
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1153
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
DRUG:
CHF 5993 100/6/12.5 µg
DRUG:
CHF 1535 100/6 µg
Sponsor
Chiesi Farmaceutici S.p.A.